Chronic Kidney Disease Market Set for Significant Growth Between 2025 and 2034 Driven by Rising Demand for Treatments

Expanding Horizons: The Chronic Kidney Disease Market Forecast

The chronic kidney disease (CKD) market is on the brink of notable expansion during the forecast period of 2025 to 2034. This growth is primarily driven by a combination of factors including the escalating global prevalence of diabetes, hypertension, and an aging population. The rising awareness surrounding CKD, coupled with advancements in early diagnosis, supports a larger pool of patients who are now eligible for treatment.

Market Overview

A recent report from DelveInsight provides an in-depth analysis of the CKD market, detailing current treatment practices, emerging drugs, and market forecasts. The report indicates that as of 2024, the CKD market size across the seven major markets (7MM) was around $4.8 billion and is expected to see further escalation by 2034. The United States currently accounts for the largest share, surpassing other regions such as the EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2024, an estimated 82 million prevalent cases of CKD were recorded across the 7MM, a number projected to rise as demographic trends evolve.

Drivers of Market Growth

Several key factors are propelling the growth of the CKD market:
1. Rising Prevalence: Current projections estimate that CKD cases will further increase due to an aging population. The DelveInsight analysis indicated that in 2024, around 82 million individuals faced prevalent cases of CKD in the 7MM.
2. Expansion of Treatment Labels: Emerging evidence suggests that current CKD therapies may expand their indications, potentially enhancing treatment efficacy and market growth.
3. Advancements in Biomarkers: New biomarkers like KIM-1 and NGAL are enabling earlier and more accurate detection of CKD, which facilitates timely intervention and improved patient outcomes.
4. Emerging Drugs: The launch of innovative therapies such as Zibotentan/Dapagliflozin, Vicadrostat + Empagliflozin, and others is expected to transform the CKD market by providing more effective treatment options.

Clinical Landscape and Emerging Therapies

The competitive landscape showcases various pharmaceutical companies actively developing new treatments for CKD. Notably, drugs currently under investigation include Zibotentan/Dapagliflozin, Baxdrostat/Dapagliflozin, and Vicadrostat + Empagliflozin from esteemed companies like AstraZeneca and Boehringer Ingelheim. These emerging therapies aim to slow CKD progression and improve patients' quality of life. AstraZeneca's Zibotentan, an endothelin A receptor blocker, combined with the SGLT2 inhibitor dapagliflozin, aims to protect kidney function while also providing cardiovascular benefits by tackling crucial disease pathways.

Moreover, Boehringer Ingelheim is advancing its investigational therapies, such as a selective aldosterone synthase inhibitor designed to avert renal damage while reducing cardiovascular risks. The promising results from recent clinical trials enhance the prospects for these therapies, showcasing their potential in the competitive landscape. ProKidney’s unique approach of utilizing autologous cell therapy through its investigational drug Rilparencel aims to stabilize or slow the decline of kidney function in patients with type 2 diabetes, demonstrating innovative therapeutic avenues in development.

Recent Developments

In 2025, ProKidney made strategic amendments to its Phase III program, accelerating the US-based PROACT 1 trial to prioritize enrollment. Furthermore, the FDA recently endorsed the eGFR slope for this investigational treatment's accelerated approval pathway, indicating a positive step forward for CKD therapies.

Understanding CKD

Chronic kidney disease is systematically characterized by a gradual loss of kidney function, leading to potential waste accumulation and fluid imbalance in the bloodstream. Symptoms often remain undetected until the later stages, making early detection critical. Common causes include diabetes and high blood pressure, and complications may include heart disease and bone weakness. Hence, effective management strategies are crucial for preserving kidney function and overall health.

Conclusion

As the CKD market continues to evolve, the anticipated launch of novel therapies stands to reshape treatment paradigms, unlocking profound opportunities for medical innovation and addressing existing patient care gaps. With the market projected to see significant growth, healthcare providers and patients alike are hopeful for advancements that will improve outcomes in chronic kidney disease management.